185 related articles for article (PubMed ID: 31713130)
21. Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections.
LaPensee K; Mistry R; Lodise T
Am Health Drug Benefits; 2019 Feb; 12(1-Supplement 2):S13-S24. PubMed ID: 30996767
[TBL] [Abstract][Full Text] [Related]
22. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
Caselli D; Mariani M; Colomba C; Ferrecchi C; Cafagno C; Trotta D; Carloni I; Dibello D; Castagnola E; Aricò M
Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255391
[TBL] [Abstract][Full Text] [Related]
23. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
O'Riordan W; Cardenas C; Shin E; Sirbu A; Garrity-Ryan L; Das AF; Eckburg PB; Manley A; Steenbergen JN; Tzanis E; McGovern PC; Loh E;
Lancet Infect Dis; 2019 Oct; 19(10):1080-1090. PubMed ID: 31474458
[TBL] [Abstract][Full Text] [Related]
24. Dalbavancin During the COVID-19 Pandemic.
Caputo WJ; Johnson ES; Fahoury G; Monterosa P
Surg Technol Int; 2022 Oct; 41():. PubMed ID: 36265122
[TBL] [Abstract][Full Text] [Related]
25. Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs.
Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
Drugs Context; 2018; 7():212559. PubMed ID: 30574170
[TBL] [Abstract][Full Text] [Related]
26. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
27. Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Garnock-Jones KP
Drugs; 2017 Jan; 77(1):75-83. PubMed ID: 27988870
[TBL] [Abstract][Full Text] [Related]
28. Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion.
Bosso JA; Casapao AM; Edwards J; Klinker K; McCoy C; Nicolau DP; Perez KK; Marcarelli A; Dua D
Hosp Pract (1995); 2016 Oct; 44(4):183-189. PubMed ID: 27598313
[TBL] [Abstract][Full Text] [Related]
29. Examination of hospital length of stay in Canada among patients with acute bacterial skin and skin structure infection caused by methicillin-resistant Staphylococcus aureus.
Potashman MH; Stokes M; Liu J; Lawrence R; Harris L
Infect Drug Resist; 2016; 9():19-33. PubMed ID: 26869806
[TBL] [Abstract][Full Text] [Related]
30. Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).
Amara S; Adamson RT; Lew I; Huang X
Curr Med Res Opin; 2013 Jul; 29(7):869-77. PubMed ID: 23659559
[TBL] [Abstract][Full Text] [Related]
31. Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus.
Claeys KC; Zasowski EJ; Trinh TD; Casapao AM; Pogue JM; Bhatia N; Mynatt RP; Wilson SS; Arthur C; Welch R; Sherwin R; Hafeez W; Levine DP; Kaye KS; Delgado G; Giuliano CA; Takla R; Rieck C; Johnson LB; Murray KP; Gordon J; Reyes K; Hartman P; Davis SL; Rybak MJ
Infect Dis Ther; 2019 Jun; 8(2):199-208. PubMed ID: 30915685
[TBL] [Abstract][Full Text] [Related]
32. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
[TBL] [Abstract][Full Text] [Related]
33. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Scott LJ
Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
[TBL] [Abstract][Full Text] [Related]
34. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
[TBL] [Abstract][Full Text] [Related]
35. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
[TBL] [Abstract][Full Text] [Related]
36. Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States.
Keyloun KR; Weber DJ; Gardstein BM; Berger A; Gillard P; Ganz ML
Hosp Pract (1995); 2018 Dec; 46(5):278-286. PubMed ID: 30067108
[No Abstract] [Full Text] [Related]
37. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
McSorley JC; Reyes D; Tonna I; Bateman V
Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
[TBL] [Abstract][Full Text] [Related]
38. Emergency department care of ABSSSI with dalbavancin infusion, direct discharge, and outpatient telemedicine follow up: a study protocol.
Durante-Mangoni E; Riccardi A; Guarino M; Cesaro F; Lugarà M; Mascolo S; Morelli L; Natale V; Andreoni M
J Chemother; 2023 Sep; 35(5):397-403. PubMed ID: 36264157
[TBL] [Abstract][Full Text] [Related]
39. Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections.
Talan DA; Mower WR; Lovecchio FA; Rothman RE; Steele MT; Keyloun K; Gillard P; Copp R; Moran GJ
Acad Emerg Med; 2021 Oct; 28(10):1108-1117. PubMed ID: 33780567
[TBL] [Abstract][Full Text] [Related]
40. Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift.
Verastegui JE; Hamada Y; Nicolau DP
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1039-45. PubMed ID: 27248789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
